πŸ“Š poll results
Moderna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?
πŸ—³οΈ 18 votes so far πŸ† Leading: The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base

Of 18 votes cast so far, The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base leads with 44%.

This is mostly a short squeeze and momentum rally -- with $5.5B in shorts getting burned, the stock's valuation has now outrun its actual shrinking sales is second on 33%, 11 points behind.

Everyone who has answered so far is voting from China.

The poll is still live and picked up a vote today.

hewsay who say wut? πŸ’¬
πŸ“Š poll results
Moderna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?
44%
Leading answer
The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base

Discussion

react to this tea πŸ‘€
The cancer vaccine data is a legitimate scientific breakthrough -- a personalized mRNA shot that meaningfully delays melanoma recurrence changes the long-term story for Moderna
The mFlusiva flu vaccine approval matters just as much -- it proves Moderna's mRNA platform can succeed well beyond COVID, diversifying its revenue base
This is mostly a short squeeze and momentum rally -- with $5.5B in shorts getting burned, the stock's valuation has now outrun its actual shrinking sales